Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When | Pediatrics | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 6,861
Citations 0
April 6, 2021

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Author Affiliations
  • 1Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Boston, Massachusetts
  • 2Division of Infectious Diseases, Department of Pediatrics, Boston Children’s Hospital, Boston, Massachusetts
  • 3Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts
JAMA Pediatr. Published online April 6, 2021. doi:10.1001/jamapediatrics.2021.0638

Death and disease in adult patients from the COVID-19 pandemic continue unabated across the world well into 2021,1 and why children have escaped severe disease from this virus2 remains one of the most intriguing gaps in our understanding of the immune response to this virus. Of equal imperative, what insights can be gained via a deeper understanding as to why some children do become critically ill from COVID-19 and the more recently described multisystem inflammatory syndrome in children (MIS-C)? Unlocking the key immunologic mechanisms driving these outcomes will likely initially emerge from meticulous epidemiologic studies that describe the few children who do get very ill from this disease.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words